Viemed Healthcare Beheer

Beheer criteriumcontroles 3/4

De CEO Viemed Healthcare is Casey Hoyt, benoemd in Dec2017, heeft een ambtstermijn van 6.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.51M, bestaande uit 20.3% salaris en 79.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.58% van de aandelen van het bedrijf, ter waarde $ 19.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.9 jaar en 6.9 jaar.

Belangrijke informatie

Casey Hoyt

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris	20.3%
Dienstverband CEO	6.9yrs
Eigendom CEO	5.6%
Management gemiddelde ambtstermijn	6.9yrs
Gemiddelde ambtstermijn bestuur	6.9yrs

Recente managementupdates

Recent updates

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Apr 11

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

Mar 07

Analyse CEO-vergoeding

Hoe is Casey Hoyt's beloning veranderd ten opzichte van Viemed Healthcare's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$10m
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	US$10m
Dec 31 2023	US$3m	US$509k	US$10m
Sep 30 2023	n/a	n/a	US$9m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	US$6m
Dec 31 2022	US$2m	US$470k	US$6m
Sep 30 2022	n/a	n/a	US$8m
Jun 30 2022	n/a	n/a	US$9m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	US$2m	US$470k	US$9m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$11m
Mar 31 2021	n/a	n/a	US$29m
Dec 31 2020	US$2m	US$441k	US$32m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$29m
Mar 31 2020	n/a	n/a	US$11m
Dec 31 2019	US$2m	US$425k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$9m
Dec 31 2018	US$2m	US$389k	US$10m
Sep 30 2018	n/a	n/a	US$7m
Jun 30 2018	n/a	n/a	US$9m
Mar 31 2018	n/a	n/a	US$8m
Dec 31 2017	US$1m	US$235k	US$8m

Compensatie versus markt: De totale vergoeding ($USD 2.51M ) Casey } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.14M ).

Compensatie versus inkomsten: De vergoeding van Casey is het afgelopen jaar met meer dan 20% gestegen.

CEO

Casey Hoyt (47 yo)

6.9yrs

Tenure

US$2,512,214

Compensatie

Mr. Casey Hoyt has been Director of Viemed Healthcare, Inc. since December 14, 2016 and Chief Executive Officer since December 2017. Mr. Hoyt served as Chief Executive Officer of Patient Home Monitoring Co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Casey Hoyt	CEO & Director	6.9yrs	US$2.51m	5.58% $ 19.0m
Michael Moore	President	6.9yrs	US$1.95m	4.75% $ 16.2m
Trae Fitzgerald	Chief Financial Officer	6.9yrs	US$826.39k	0.17% $ 581.3k
William Zehnder	COO & Director	6.9yrs	US$1.94m	0.57% $ 2.0m
Jerome Cambre	Vice President of Sales	6.7yrs	US$805.30k	0.19% $ 651.5k
William Frazier	Chief Medical Officer & Director	6.9yrs	US$328.08k	0.17% $ 593.3k
Jeremy Trahan	EVP, Chief Legal Officer & Corporate Secretary	2.3yrs	geen gegevens	0.028% $ 97.0k
Michael Freeman	Chief Business Development Officer	2.3yrs	geen gegevens	geen gegevens

6.9yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VMD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Casey Hoyt	CEO & Director	7.9yrs	US$2.51m	5.58% $ 19.0m
William Zehnder	COO & Director	6.9yrs	US$1.94m	0.57% $ 2.0m
William Frazier	Chief Medical Officer & Director	6.9yrs	US$328.08k	0.17% $ 593.3k
Randolph Dobbs	Independent Chairman	6.9yrs	US$221.63k	0.28% $ 942.4k
Nitin Kaushal	Independent Director	6.9yrs	US$202.00k	0.33% $ 1.1m
Sabrina Heltz	Independent Director	4yrs	US$191.00k	0.13% $ 452.9k
Timothy Smokoff	Independent Director	6.9yrs	US$204.00k	0.24% $ 802.0k
Bruce Greenstein	Independent Director	6.3yrs	US$199.63k	0.20% $ 670.7k

6.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).

Viemed Healthcare Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

CEO & Director exercised options and sold US$182k worth of stock

Insufficient new directors

Viemed Announces Management Appointments

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 7.8% to US$12.75

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Consensus EPS estimates fall by 19%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

CEO & Director exercised options and sold US$182k worth of stock

Third quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Price target increased by 15% to US$15.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

Insufficient new directors

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Viemed Healthcare: Comments On Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Healthcare Q2 2022 Earnings Preview

Viemed Announces Management Appointments

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare: New Bullish Trend Has Just Begun

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Viemed Healthcare, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Viemed Healthcare EPS misses by $0.01, revenue in-line

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$10.80

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance

Investor sentiment improved over the past week

New 90-day high: US$9.83

Strong Execution By Insider-Owners Ensures Viemed's Growth

Viemed Healthcare Announces Recent Publication of Non-Invasive Ventilation Study

New 90-day low: US$7.92

Viemed Healthcare, Inc. (TSX:VMD) acquired 5% stake in VeruStat, Inc for approximately $0.6 million.

Viemed Healthcare, Inc. Appoints Sabrina Heltz to the Board and to Serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board

Third quarter 2020 earnings released: EPS US$0.072

Revenue beats expectations, earnings disappoint

Viemed Healthcare EPS misses by $0.02, beats on revenue

Market pulls back on stock over the past week

New 90-day low: US$8.01

New 90-day low - US$8.92

First half earnings released